ReviewExperimental & molecular medicine2025
Progressing future osteoarthritis treatment toward precision medicine: integrating regenerative medicine, gene therapy and circadian biology.
Review in Experimental & molecular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- HIF-PH Inhibitor Promotes Stabilization of HIF-1α via Inhibition of Its Degradation and Exerts Chondroprotective Effects in a Rat Osteoarthritis Model.International journal of molecular sciences · 2026Article
- Species-specific roles of cellular communication network proteins in cartilage development: A comparative study using in vitro chondrogenic models.Journal of cell communication and signaling · 2026Article
- p21 Knockdown as a Therapeutic Strategy for Focal Cartilage Injury Repair.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026Article
- A review of the circadian regulation of stem cells: harnessing the internal body clock for enhanced regenerative therapies.Stem cell research & therapy · 2026Review
- Advancement on localized targeting via intra-articular administration of lipid-based vesicular nanoparticles for osteoarthritis management.Journal of nanobiotechnology · 2026Review
- Epigenetic regulation in osteoarthritis: recent updates and emerging mechanisms.Frontiers in genetics · 2026Review
- Recent Advances in Therapeutic Approaches for Knee Osteoarthritis: a Narrative Review.Biomolecules & therapeutics · 2026Review
- Hyaluronic Acid-Modified Celecoxib-Loaded Nanostructured Lipid Carriers Combined with Dissolving Microneedles for Targeted Sustained-Release Therapy in Osteoarthritis.International journal of nanomedicine · 2026Article
- Molecular mediators of motion: RNA-RBP networks in exercise-induced osteoarthritis protection.Frontiers in genetics · 2026Review
- Investigating the Mechanistic Link Between Lactate-Induced Histone Lactylation and Cellular Senescence in Osteoarthritis Chondrocytes: Implications for Therapy.International journal of biological sciences · 2026Article
- Focus on necroptosis: its role in the pathogenesis and therapeutic potential of osteoarthritis.Frontiers in immunology · 2026Review
- A Multidimensional Definition of Pre-Osteoarthritis: Toward 21st-Century Subclinical Detection and Targeted Intervention.International journal of molecular sciences · 2025Review
- A New Way to Engineer Cell Sheets for Articular Cartilage Regeneration.Journal of functional biomaterials · 2025Article
- Network Toxicology and Molecular Docking Reveal the Toxicological Mechanisms of DEHP in Bone Diseases.International journal of molecular sciences · 2025Article
- Comparative analysis of adipose-, bone marrow-, and amniotic membrane-derived MSC secretomes and EVs reveals shared and source-specific therapeutic signatures for osteoarthritis.Extracellular vesicles and circulating nucleic acids · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Osteoarthritis (OA) is marked by cartilage degradation, inflammation and varied pain. Traditional treatments such as nonsteroidal anti-inflammatory drugs primarily offer symptom relief without halting disease progression. Advances in regenerative medicine and stem cell and gene therapies, combined with innovative biomaterials such as hydrogels, present new opportunities to target the underlying pathophysiology of OA. This review explores these promising approaches alongside the emerging roles of circadian biology and organelle health in OA pathogenesis and therapy. It highlights the shift toward precision medicine, offering a comprehensive analysis of emerging targeted strategies aimed at improving OA management and patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.